
    
      A Phase I, dose-escalation, pilot study designed to obtain safety and tolerability data on
      visilizumab administered to patients with severe ulcerative colitis that has failed to
      respond to steroid therapy. Patients who are currently receiving IV corticosteroids, but
      whose disease has not responded after at least 5 days of this therapy, will be eligible for
      the study.
    
  